FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns a composition of Dimexid gel for outward application exhibiting anti-inflammatory action in the integrated treatment for relief of pain syndrome of various aetiologies (rheumatoid arthritis osteoarthrosis deformans, arthropathy, radiculitis, trigeminal neuralgia, etc.), for treatment of bruises, sprains of ligaments, traumatic infiltrates, treatment of erythema nodosum. There is offered a composition containing Dimexid, sodium carmellose (sodium carboxymethylcellulose), methylparahydroxybenzoate (Nipagin), propylparahydroxybenzoate (Nipasol) and water.
EFFECT: preparation represents a stable, accessible dosage form of Dimexid.
3 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIMEXIDE GEL POSSESSING ANTI-INFLAMMATORY ACTION | 2024 |
|
RU2838731C1 |
| COMPOSITION FOR TOPICAL APPLICATION IN THE TREATMENT OF ONYCHOMYCOSIS (OPTIONS) | 2022 |
|
RU2786851C1 |
| ANTISPASMODIC, DIURETIC AND ANTI-INFLAMMATORY DRUG (VERSIONS) | 2024 |
|
RU2836881C1 |
| PHARMACEUTICAL COMPOSITION OF SEDATIVE AND ANXIOLYTIC ACTION | 2020 |
|
RU2737701C1 |
| ANTISPASMODIC, ANTIULCER AND ANTACID AGENT | 2021 |
|
RU2784057C1 |
| DRUG WITH SPASMOLITHIC, DIURETIC AND LITHIOLIC ACTION | 2017 |
|
RU2635459C1 |
| DRUG WITH LITHOLITHIC, DIURETIC AND ANTI-INFLAMMATORY ACTION | 2017 |
|
RU2635196C1 |
| ARTHRONOSOS CURE | 2007 |
|
RU2353349C2 |
| AGENT FOR TREATING ORAL CANDIDIASIS | 2021 |
|
RU2780094C1 |
| PHYTOMIXTURE WITH SEDATIVE EFFECT | 2013 |
|
RU2554796C2 |
